Fierce Biotech Next Gen 2022: Full Schedule

9:30am EDT

Alzheimer’s: What comes after Aduhelm?

The FDA surprised many with a biomarker-based approval for Biogen’s Aduhelm—and in the process energized the field. As Alzheimer’s R&D surges, we’ll discuss what’s next for the major players and the upstarts looking to compete with them.

Moderators

Annalee Armstrong

Senior Editor, Fierce Biotech

Annalee Armstrong is a senior editor for Fierce Biotech. Prior to joining Fierce in April 2021, Annalee was an associate editor for S&P Global Market Intelligence’s healthcare news team. Before that, she was the EPA reporter covering climate and energy policy on the Hill in Washington... Read More →

Speakers

Brandy Matthews, M.D., FAAN

Associate Vice President, Global & U.S. Medical Affairs, Alzheimer’s Disease, Eli Lilly and Company

Brandy Matthews, M.D., FAAN, is the associate vice president of global & US medical affairs for Eli Lilly and Company.Since joining Lilly in 2015, Brandy has held a range of roles within the clinical and medical affairs space, serving as CRP in global medical affairs before transitioning... Read More →

Gregory A. Rippon, MD, MS

Vice President and Chief Medical Partner, Neurology, Genentech

Gregory A. Rippon, MD, MS is Vice President and Chief Medical Partner, Neurology, Ophthalmology and Internal Medicine at Genentech. In his role, Dr. Rippon leads U.S. medical affairs portfolio and pipeline medical programs across these therapeutic areas and is a member of the U.S... Read More →

Brandon Pence

VP & GM, Cell Biology, Thermo Fisher Scientific

Brandon Pence has more than 20 years of experience in the life sciences industry leading teams in R&D, product management, marketing and business strategy. Brandon began his career at Thermo Fisher Scientific in R&D and spent more than 15 years in a variety of technical and business... Read More →

Roger Lane, MD, MPH

Senior Vice President, Ionis Pharmaceuticals, Inc.

Roger Lane, MD, MPH: Head of Clinical Development Neurology at Ionis Pharmaceuticals for last 8 years, conducting clinical development of ASOs for common, rare and ultra-rare neurological disorders, including an ASO targeting MAPT RNA for degradation that will soon enter Phase 2... Read More →

Wednesday June 29, 2022 9:30am - 10:30am EDT

Panel Discussion

10:30am EDT

Innovation Insights: An Analysis of the Evolving Landscape of Nucleic Acid-Based Therapeutics

In recent years we have seen rapid evolution of nucleic acid-based therapeutics and vaccines. Is this evolution leading to the formation of a new technology toolbox? Can this toolbox leverage desired characteristics across a range of molecule types, based on therapeutic need? How do we consider the implications of modalities that stretch from truly personalized medicines through to global vaccine initiatives? In this presentation we will review current scientific research and analyze how this impacts upon the industrialization of flexible manufacturing.

Speakers

Tracy Humphries

mRNA Segment Marketing Leader, Cytiva

Tracy is a biologist with over twenty years’ experience of life science, marketing and sales across varied market and industry segments. She focuses on areas of innovation, development and commercialization of products and solutions.

Wednesday June 29, 2022 10:30am - 10:50am EDT

Keynote

10:50am EDT

Executive Interview: Jason Martin, Vice President, Cell Therapy Operations Global Manufacturing Science and Technology, Bristol Myers Squibb

Moderators

Fraiser Kansteiner

Staff Writer, Fierce Pharma

Fraiser Kansteiner is a staff writer at Fierce Pharma. He joined the Fierce team in 2020 and covers topics such as manufacturing, COVID-19 and drug delivery. He also manages Fierce Biotech and Fierce Pharma’s LinkedIn showcase pages. Before diving into pharma reporting, Fraiser... Read More →

Speakers

Jason Martin

Vice President, Cell Therapy Operations Global Manufacturing Science & Technology, Bristol Myers Squibb

Jason has over 25 years of biopharmaceutical experience at industry leading companies BMS, Celgene, Novartis, and Merck & Co. Inc. He is currently the Vice President, Cell Therapy Operations, Global Manufacturing Science & Technology at BMS where he leads a global team supporting... Read More →

Wednesday June 29, 2022 10:50am - 11:10am EDT

Executive Interview

11:10am EDT

From Clinical to Commercialization: Best Practices for an Integrated Advanced Therapies Value Chain

With the growing complexities of Cell and Gene treatment journeys in a post-pandemic world, the supply chain continues to have many unique challenges. Join patient-centric supply chain expert Bengt-Simon Feth to discuss how to accelerate advanced therapy clinical trials through cell and gene supply chain customization.

This presentation will explore:

Key obstacles of delivering personalized medicine including regulatory hurdles
Strategic solutions for an integrated value chain
Valuable lessons learned and best practices to accelerate the scale and availability of advanced therapies

Speakers

Bengt-Simon Feth

Senior Global Director, Cell and Gene Supply Chain, Marken

Bengt-Simon Feth is the Senior Global Director of Cell and Gene Supply Chain for Marken. Simon has spent eight years at Marken growing global operations for Direct-to-Patient, Clinical Trial Distribution, and Cell and Gene Therapy. Simon has over 15 years of experience working in... Read More →

Wednesday June 29, 2022 11:10am - 11:30am EDT

Presentation

11:30am EDT

Executive Interview: Matthew Truppo, PhD, Global Head of Research Platforms, Sanofi

Moderators

James Waldron

Senior Writer, Fierce Biotech

James is UK/EU bureau chief for Fierce Biotech. Prior to joining Fierce in April 2022, James oversaw S&P Global Market Intelligence’s coverage of the pharma, biotech and hospital sectors as healthcare industry editor. Before that, he spent eight years covering the U.K. community... Read More →

Speakers

Matthew Truppo, Ph.D.

Global Head of Research Platforms, Sanofi

Matt Truppo currently serves as Global Head of Research Platforms for Sanofi. He oversees the full range of research platform capabilities, including Integrated Drug Discovery, Large Molecule Research, Drug Metabolism & Pharmacokinetics, Translational In Vivo Models, and Pre-Clinical... Read More →

Wednesday June 29, 2022 11:30am - 11:50am EDT

Executive Interview

11:50am EDT

Translating mRNA-Based Medicines from Concept to Clinic

RNA can be designed to silence, express and edit specific genes, providing a flexible and powerful approach to treating diseases. COVID-19 mRNA vaccines, while an extraordinary accomplishment, have revealed that rapid development and scale-up, as well as access to innovative technologies, are needed to keep up with emerging variants and to usher in a new wave of genomic medicines to address other areas of unmet medical need. In this presentation, we will share insights on cutting-edge technologies accelerating the development of RNA-lipid nanoparticle-based medicines from discovery to commercialization.

Speakers

Lloyd Jeffs

Senior Director, Pharmaceutical Development, Precision NanoSystems

Lloyd Jeffs is the Senior Director of Pharmaceutical Development at Precision NanoSystems. His Biopharmaceutical Services team is responsible for developing and executing custom programs to support the clinical manufacturing needs of Precision NanoSystems’ clients. Lloyd is... Read More →

Wednesday June 29, 2022 11:50am - 12:10pm EDT

Presentation

12:10pm EDT

Networking Break

Wednesday June 29, 2022 12:10pm - 1:00pm EDT

Networking

1:00pm EDT

AI in Drug Discovery Grows Up

Artificial intelligence has been hailed as a game-changer in drug discovery for years—and now, it might actually be changing the game. A flurry of partnerships between AI companies and drugmakers in recent months—and some high-profile successes—are once again spotlighting this high-tech method of finding targets and the drugs that might hit them.

Moderators

Conor Hale

Senior Editor, Fierce Biotech

Conor Hale is a senior editor writing for FierceMedTech and FierceBiotech. He has previously covered the pharmaceutical and medical research industries in the Washington, D.C., area for The Cancer Letter and FDAnews. Conor graduated from St. Bonaventure University’s journalism school... Read More →

Speakers

Andrew Hopkins

Chief Executive Officer and Executive Director, Exscientia

Andrew is one of the most distinguished and cited scientists in modern drug discovery. As part of his role as founder and CEO of Exscientia, he invented and championed an automated and algorithmic approach to drug design and drug discovery. Prior to that, he spent 14 years at Pfizer... Read More →

Gregory Verdine, Ph.D.

Founder and CEO, LifeMine Therapeutics and FogPharma

Gregory Verdine is an award-winning university educator, pioneering scientist and innovator, life science entrepreneur, venture capitalist and successful biotech company-builder. He currently serves as the co-founder and CEO of both LifeMine Therapeutics, a biotechnology company reinventing... Read More →

Iker Huerga

Chief Data Scientist, Oncology R&D, AstraZeneca

Iker Huerga joined AstraZeneca in 2020 as the Chief Data Scientist for Oncology R&D in AstraZeneca, where he oversees all Data Science activities across Early Oncology and Late Development Oncology at AstraZeneca. In addition to his role at AstraZeneca, Huerga serves as the Senior... Read More →

Andrew A. Radin

CEO & Co-Founder, Aria Pharmaceuticals

Andrew A. Radin is the co-founder and Chief Executive Officer of Aria Pharmaceuticals. Andrew created the company’s first drug development algorithms as part of his studies in biomedical informatics at Stanford University in 2014. Since co-founding Aria, Andrew was named an Emerging... Read More →

Wednesday June 29, 2022 1:00pm - 2:00pm EDT

Panel Discussion

2:00pm EDT

Bringing Gene Therapies to Life: Navigating Scale Up, Leveraging Partnerships and Breaking Down Barriers to Make These a Reality

Cell and gene therapies are rapidly advancing and with that, the need to effectively generate large volumes of viable cell and gene therapy products to fuel the pipeline. In this fast-paced industry, researchers, manufacturers, life science companies, and academics are working together to solve significant challenges. Join Corning and Expression Therapeutics in a discussion about their experiences transitioning from R&D to upstream manufacturing for gene therapies: navigating many variables and overcoming obstacles to innovate the process and make novel gene therapies a reality.

This discussion will cover:

Key challenges and considerations for moving gene therapies into clinical trials
How to overcome challenges in manufacturing with creative thinking to push technologies forward
How industry partnerships are evolving and how you can leverage them to drive innovation

Moderators

Ben Josey Ph.D.

Field Application Scientist, Corning Life Sciences

Dr. Ben Josey is a Field Application Scientist at Corning Life Sciences. He received his Ph.D. in Pharmaceutical and Biomedical Sciences from the Medical University of South Carolina working on small molecule and biomaterial-based treatments for cancer and neurodegenerative disease... Read More →

Speakers

William Swaney, M.S.

President, Expression Manufacturing LLC

Mr. Swaney is the President of Expression Manufacturing LLC and a renowned vector manufacturing expert. He recently oversaw the buildout of Expressions in house manufacturing cell and gene therapy manufacturing facility. He has three decades of experience in biopharmaceutical manufacturing... Read More →

Gabriela Denning, Ph.D.

Vice President of Research & Development, Expression Therapeutics

Dr. Denning has over 15 years of preclinical development experience in the cell and gene therapy industry with a focus on lentiviral-based gene therapies. Her experience spans preclinical development to IND-enabling studies and has led various successful regulatory submissions for... Read More →

Anindya Dasgupta, Ph.D.

Director GMP Manufacturing, Expression Manufacturing LLC

Dr. Dasgupta is the Director of GMP, at Expression Manufacturing LLC. Previously he was the Director of Vector Development. He has more than fifteen years of experience in the field of cell and gene therapy. In his previous position as a Research Associate at Emory University, School... Read More →

Wednesday June 29, 2022 2:00pm - 2:20pm EDT

Presentation

2:20pm EDT

Executive Interview: Ulrike Buchwald, Executive Director and Section Head for Pneumococcal Vaccines Research, Merck Research Laboratories (MRL)

Moderators

Kevin Dunleavy

Staff Writer, Fierce Pharma

Kevin Dunleavy is a staff writer for Fierce Pharma. He joined the Fierce team after working 26 years as a newspaper sportswriter. He compiles Fierce Pharma’s COVID Tracker and writes about manufacturing and other topics. Kevin is a longtime resident of Northern Virginia and a graduate... Read More →

Speakers

Ulrike Buchwald

Executive Director and Section Head for Pneumococcal Vaccines Research, Merck Research Laboratories (MRL)

Ulrike Buchwald, MD, is Executive Director and Section Head for Pneumococcal Vaccines Research at Merck Research Laboratories (MRL). She is board certified in internal medicine and adult infectious diseases with broad experience in infectious diseases research and practice in academia... Read More →

Wednesday June 29, 2022 2:20pm - 2:40pm EDT

Executive Interview

2:40pm EDT

Executive Interview: Ryan Potts, Ph.D., Executive Director, Research and Head of the Induced Proximity Platform, Amgen, Inc.

Moderators

Gabrielle Masson

Staff Writer, Fierce Biotech

Gabrielle Masson is a staff writer for Fierce Biotech. Prior to Fierce, she worked at Becker's Hospital Review for nearly three years, where she reported on public health and the pandemic. Gabrielle graduated from the University of Wisconsin-Madison in 2019 after studying creative... Read More →

Speakers

Ryan Potts, Ph.D.

Executive Director, Research and Head of the Induced Proximity Platform, Amgen, Inc.

In 2020, Ryan Potts, Ph.D., joined Amgen to build a new department called the Induced Proximity Platform (IPP) that is focused on drugging the “undruggable”. Dr. Potts obtained his B.S. in Biology from the University of North Carolina and his Ph.D. in Cell and Molecular Biology... Read More →

Wednesday June 29, 2022 2:40pm - 3:00pm EDT

Executive Interview

9:30am EDT

What are Cell and Gene Therapies Worth?

Drugmakers are pouring billions into developing advanced therapies that manipulate cells—or the genome—to treat or cure disease. But with price tags in the millions, these therapies are a challenge for payers. How can companies demonstrate their worth to the payers that have to foot the bill? And how are payers coping with their advance?

Moderators

Eric Sagonowsky

Senior Editor, Fierce Pharma

Eric Sagonowsky is an editor with the FierceMarkets Life Sciences team. Before joining Fierce in November 2014, Eric worked as a news reporter for the Manistee News Advocate in Manistee, Mich., covering government and crime issues. Eric graduated from Ohio University's E.W. Scripps... Read More →

Speakers

Steven D. Pearson, M.D., MSc

President, Institute for Clinical and Economic Review (ICER)

Steven D. Pearson, MD, MSc is the Founder and President of the Institute for Clinical and Economic Review (ICER), an independent non-profit organization that evaluates the evidence on the value of medical tests, treatments, and delivery system innovations to encourage collaborative... Read More →

Tay Salimullah

Vice President, Head Global Value & Access, Novartis Gene Therapies

Tay is Vice President, Global Head of Value & Access, currently building a 21st century integrated access function to transform rare diseases through gene therapies. Overseeing translational access; gene pricing & contracting, geneconomics; real-world data; and public policy. He has... Read More →

Brett Sahli

Assistant Vice President, Pharmaceutical Trade Relations, Prime Therapeutics

As assistant vice president, pharmaceutical trade relations at Prime Therapeutics (Prime), Brett Sahli is responsible for leading the strategy for optimal medical drug management, strategic analytic services, and product development initiatives for drug management. Using integrated... Read More →

Kelley Miller

Senior Director, Managed Markets, Optum Frontier Therapies

As senior director of managed markets for Optum Frontier Therapies, a specialty pharmacy dedicated to people with rare disease, Kelley Miller manages all client-facing responsibilities for payer contracting and relationship development. He has deep experience in business development... Read More →

Thursday June 30, 2022 9:30am - 10:30am EDT

Panel Discussion

10:30am EDT

Investing for Commercial Success as an Emerging Company

Whether or not the plan is to partner, out-license or go it alone, executives at emerging companies need to understand what levels of spend are appropriate to prepare a product for a successful launch. A strategic analysis of influential factors, such as level of development risk, corporate strategy, customer base characteristics and competitive landscape can help these companies determine whether to spend more or less, earlier or later in the process as they bring their product to market.

Based on five years of survey data and market analysis, this session will drill down on perception versus reality around level of investment needed – and where to spend – for a successful product launch.

Speakers

Sachin Purwar

Managing Director, Syneos Health

Sachin Purwar brings over 18 years of pharmaceutical industry experience to Syneos Health Consulting along with a strong analytical and sales background. He has broad experience working across the firm’s Commercial Advisory Group with a focus on portfolio and commercial strategy... Read More →

Thursday June 30, 2022 10:30am - 10:50am EDT

Keynote

10:50am EDT

Executive Interview: Andrew Adams, VP-Neurodegeneration Res & Co-Director, Lilly Institute for Genetic Medicines

Moderators

Max Bayer

Staff Writer, Fierce Biotech

Max Bayer is a staff writer for Fierce Biotech. He joined after more than three years at CBS News, two of which were spent covering the twists and turns of the COVID-19 pandemic, from infection trends to CDC guidelines. He graduated from the University of Wisconsin-Madison in 2018... Read More →

Speakers

Andrew Adams, Ph.D.

VP-Neurodegeneration Res & Co-Director, Lilly Institute for Genetic Medicines

Dr. Andrew Adams serves VP-Neurodegeneration Research & Co-Director of Lilly Institute for Genetic Medicines. He previously served as Vice President for Lilly Genetic Medicine. In this role, Andrew is responsible for leading the discovery of new types of therapies, such as genetic... Read More →

Thursday June 30, 2022 10:50am - 11:10am EDT

Executive Interview

11:10am EDT

Executive Interview: Max Lataillade, Vice President, Head of Global Research Strategy, ViiV Healthcare

Moderators

Annalee Armstrong

Senior Editor, Fierce Biotech

Speakers

Max Lataillade

Vice President, Head of Global Research Strategy, ViiV Healthcare

Max Lataillade is responsible for global research and development strategy for the HIV pipeline at ViiV Healthcare, the only company 100% dedicated to HIV. He oversees end-to-end R&D activities for all novel HIV pipeline programs designed to address key unmet medical needs for people... Read More →

Thursday June 30, 2022 11:10am - 11:30am EDT

Executive Interview

11:30am EDT

Executive Interview: Dr. Kim Branson, SVP and Global Head of Artificial Intelligence and Machine Learning, GSK

Moderators

Andrea Park

Staff Writer, Fierce Pharma

Andrea Park is a staff writer for Fierce Medtech. Prior to joining the Fierce team, she covered hospital IT and innovation at Becker’s Hospital Review and made good use of her pop culture expertise as a reporter and editor at Marie Claire, W, People and more. A graduate of Northwestern... Read More →

Speakers

Dr. Kim Branson

Senior Vice President and Global Head of AI/ML, GSK

Dr Kim Branson is SVP, Global Head, AI/ML at GSK, based in San Francisco. Kim leads the GSK.ai team, a global organization of nearly 100 machine learning researchers and engineers who are pioneering the application of AI to drug discovery and development.Kim brings a deep expertise... Read More →

Thursday June 30, 2022 11:30am - 11:50am EDT

Executive Interview

11:50am EDT

Networking Break

Thursday June 30, 2022 11:50am - 1:00pm EDT

Networking

1:00pm EDT

The E in ESG: How Biopharma is Tackling Carbon Neutrality

Biotech and pharma’s work to diversify employee rosters, board rooms and clinical trials has drawn quite a bit of attention as investors increasingly zero in on ESG measures. Here we’ll look at the first letter of that equation—the environment—as more and more companies roll out campaigns to save energy, curb pollution and generally go carbon-neutral.

Moderators

Fraiser Kansteiner

Staff Writer, Fierce Pharma

Speakers

Jason Snape

Global Head of Environmental Protection, AstraZeneca

Professor Jason SnapeGlobal Head of Environment within AstraZeneca’s Global Sustainability Team. Accountable for AstraZeneca’s global ambitions to deliver its Ambition Zero Carbon strategy, drive natural resource reduction and ensure the environmental safety of pharmaceuticals... Read More →

Katrine DiBona

Corporate Vice President, Global Public Affairs and Sustainability, Novo Nordisk Inc.

Katrine DiBona is the Corporate Vice President of Global Public Affairs and Sustainability in Novo Nordisk. The overarching ambition of Katrine and her team of approx. 75 dedicated colleagues is to drive, nudge and support Novo Nordisk towards being a sustainable business. To Novo... Read More →

Lara Ramsburg

Head of Corporate Affairs, Viatris

Lara Ramsburg is Head of Corporate Affairs for Viatris, with responsibility for protecting and advancing the company’s reputation across stakeholder groups through strategic communications and outreach strategies aligned with the company’s mission to empower people worldwide to... Read More →

Jim Weidner

Executive Director of Engineering Technical Authority, Amgen

Jim Weidner currently serves as the Executive Director for the Engineering Technical Authority (ETA) group. Jim has 27 years of experience with Amgen, Hoffmann-La Roche, and Biogen Idec. Jim joined the ETA in July 2020. His current role includes developing innovative facility designs... Read More →

James Goudreau

Head of Environmental Sustainability External Engagement, Novartis

James Goudreau currently serves as the Head of Environmental Sustainability External Engagement for Novartis Customer and Technology Solutions. He crafts strategy and policy for Novartis to increase climate resilience, reduce GHG emissions and increase energy resilience across their... Read More →

Thursday June 30, 2022 1:00pm - 2:00pm EDT

Panel Discussion

2:00pm EDT

Executive Interview: Daniel J. Anderson, Ph.D., Chief Scientific Officer, Eikon Therapeutics

Moderators

Max Bayer

Staff Writer, Fierce Biotech

Speakers

Daniel J. Anderson, Ph.D.

Chief Scientific Officer, Eikon Therapeutics

Dan Anderson is Eikon’s Chief Scientific Officer and leads all drug discovery functions at the Company. Prior to joining Eikon, Dan was Vice President of Biology at Recursion Pharmaceuticals, a company industrializing phenotypic screening and utilizing machine learning to disrupt... Read More →

Thursday June 30, 2022 2:00pm - 2:20pm EDT

Executive Interview